Product Images Fesoterodine Fumarate

Each tablet of ASCEnD contains 4mg of fesoterodine fumarate, and is film-coated. The usual dosage is not available, and prescribing information must be adhered to. These extended-release tablets must be stored in an unvarnished area between 15°C and 30°C, protected from moisture. They measure 45x20mm (LxH). This medication is manufactured by Alkem Laboratories Ltd. and distributed by Ascend Laboratories LLC. A patient information leaflet should be included with the package. This medication is only available via prescription.*

This text appears to be a combination of a description of a medication called Fesoterodine Fumarate and packaging instructions. The medication comes in a form of extended-release, film-coated tablets that contain 8mg of Fesoterodine Fumarate. The tablets should be stored between 15 and 30 degrees Celsius and protected from moisture. A pharmacist should dispense the medication with an information leaflet for the patient. The manufacturer is Alkem Laboratories Ltd. and the medication is distributed by Ascend Laboratories LLC in Parsippany, NJ.*

The text describes a graph or figure showing the change in urge incontinence episodes per 24 hours over the course of several weeks. The figure includes a comparison between two treatments, one labeled as "placebo" and the other as "fesoterodine fumarate." The mean change from baseline is given for each treatment. No further information is available.*

The text is presenting a figure titled “Change in Number of Micturitions per 24 h (Study 2)”. The figure consists of a graph with the X-axis representing the weeks of the study and the Y-axis representing the number of micturitions per 24 hours. However, due to errors, the drug names and dosages cannot be accurately determined from the provided text.*

The text includes a figure labeled "Figure 4" representing the change in Urge Incontinence Episodes per 24 h over time (Weeks 0, 2, and 8) for two groups of patients: one group receiving Fesoterodine Fumarate ER Tablets (n=228) and the other group receiving a placebo (n=218).*